Dare Bioscience, Inc. 8-K

What Happened
Dare Bioscience, Inc. (DARE) filed an 8-K (Item 3.01) reporting that on July 13, 2026 the Nasdaq Listing Qualifications Staff notified the company it no longer complies with Nasdaq Listing Rule 5550(b). Nasdaq’s notice was based on the company’s Form 10‑Q for the quarter ended March 31, 2026, which reported stockholders’ equity of less than $2.5 million. The company said it will timely request a hearing before a Nasdaq Hearing Panel to stay any suspension or delisting while the hearing and any Panel-granted extension are pending.

Key Details

• Filing date: 8‑K signed July 17, 2026 (notice received July 13, 2026).
• Rule cited: Nasdaq Listing Rule 5550(b) (minimum stockholders’ equity requirement).
• Alternatives not met as of July 13, 2026: $35 million market value of listed securities or $500,000 net income from continuing operations.
• Company action: intends to request a hearing before a Nasdaq Hearing Panel; request will stay delisting pending the Panel’s decision and any extension. The filing notes no assurance the Panel will grant an extension or that the company will regain compliance.

Why It Matters
A Nasdaq delisting or prolonged notice of noncompliance can materially affect a company’s stock liquidity, marketability and investor confidence. The company’s immediate step to request a hearing pauses enforcement for now, but there is no guarantee of a favorable outcome or of regaining compliance. Investors should monitor future 8‑Ks and company disclosures for any Panel decisions, extension details, or a concrete plan the company may announce to restore compliance.